|
|
|
|
|||||
|
|
|
Chicago, IL – August 22, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Health Care Select Sector SPDR XLV, SPDR S&P 500 ETF Trust SPY, UnitedHealth UNH, Regeneron REGN, CVS Health CVS and Novo Nordisk NVO.
U.S. healthcare stocks are currently trading at the biggest discount relative to the broader market in 30 years, according to Barrons, presenting a solid opportunity for investors looking for stability and potential growth.
The Health Care Select Sector SPDR, which mirrors the sector’s performance, has fallen 9.6% over the past year while the broad SPDR S&P 500 ETF Trust climbed about 16%. This has pushed healthcare stocks to trade at a historic valuation discount compared to the broader market.
The sector has been struggling due to concerns over political and regulatory uncertainties, including government policies targeting prescription drug prices, tariffs on pharmaceuticals, and reduced funding in health research and Medicaid. The expiry of drug patents and setbacks faced by major companies have contributed to the sector's struggles.
In another sign of waning investor interest, healthcare ETFs have recorded 12 straight months of net outflows through July, totaling $11.5 billion. This represents the largest outflow of any sector, according to State Street Investment Management.
The healthcare sector has gathered momentum with XLV gaining 4.2% over the past week versus a decline of 0.5% for SPY. This signals potential turnaround and came on the back of attractive valuation and growing hedge fund’s exposure.
The sector is currently trading at a forward P/E ratio of around 16, substantially lower than the S&P 500's P/E ratio of about 22 and far below technology's P/E ratio of 30. This discount is the widest seen in three decades, making healthcare stocks some of the most undervalued in the market relative to their earnings potential.
Warren Buffett’s Berkshire Hathaway investment in UnitedHealth lifted sentiment, bolstering confidence in managed-care names. In the latest 13F filing, Berkshire Hathaway disclosed that it bought more than 5 million shares in UNH in the second quarter, valued at approximately $1.6 billion. The stock has soared more than 10% in a week (read: Insights Into 13F Filings: ETFs to Invest in Like Billionaires).
Per the latest 13F filings, most hedge funds ramped up exposure to healthcare stocks. Stanley Druckenmiller, renowned investor and head of Duquesne Family Office, has increased his exposure to healthcare stocks as part of a strategic portfolio adjustment during the second quarter. His portfolio, valued at around $3.06 billion, shows a prominent tilt toward innovative healthcare and pharmaceuticals, reflecting his confidence in the sector's growth potential.
Fund managers also highlighted exposure to Regeneron and other life sciences names via both equity and calls, showing targeted science-driven bets.
Stocks like CVS Health gained on analyst upgrades. Novo Nordisk surged following the FDA approval for a new use of its weight-loss drug (read: NVO Wins FDA Approval for MASH Treatment: ETFs Likely to Gain).
Amid growing skepticism over lofty tech valuations, investors are shifting toward more stable, defensive sectors. This has helped healthcare stocks attract renewed attention as a safer haven. Healthcare generally outperforms during periods of low growth and high uncertainty, as evidenced in the current macro environment.
The emergence of AI-driven healthcare initiatives, such as the Stargate project, promised to revolutionize cancer research and healthcare technologies. This created optimism about innovation-led growth in the sector, attracting investments focused on AI and biotech companies advancing healthcare solutions.
The potential upside to the healthcare sector is confirmed by the Zacks Sector Rank in the top 44%, with about 75% of the industries ranking in the top 41%. This suggests that the momentum built up in the healthcare space lately will likely continue in the coming weeks.
Zacks' exclusive Fund Newsletter delivers actionable information, top news and analysis, as well as top-performing ETFs, straight to your inbox every week.
Don’t miss out on this valuable resource. It’s free!
Get it now >>
Zacks Investment Research
800-767-3771 ext. 9339
https://www.zacks.com
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
This article originally published on Zacks Investment Research (zacks.com).
| 56 min | |
| 1 hour | |
| 1 hour | |
| 1 hour | |
| 3 hours | |
| 4 hours | |
| 4 hours | |
| 4 hours | |
| 5 hours | |
| Aug-21 | |
| Aug-21 | |
| Aug-21 | |
| Aug-21 | |
| Aug-21 | |
| Aug-21 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite